Malignancies of the Paranasal Sinus


Key Points

  • Paranasal sinus malignancies present insidiously and have poor survival outcomes due in part to advanced stage at initial diagnosis.

  • Substantial heterogeneity in histology and corresponding biologic aggressiveness is encountered, with squamous cell carcinoma and rhabdomyosarcoma being the most common in adults and children, respectively.

  • Advances in imaging, radiation modalities, and surgical approaches are crucial to clinical decision-making and have improved the morbidity and mortality associated with treatment.

  • Regardless of surgical approach used, sound oncologic principles involving complete resections with negative margins must be exercised to ensure the best patient outcomes.

Introduction

Despite advances in diagnosis and treatment, paranasal sinus malignancies continue to pose significant management challenges. As a rare, understudied cancer with a diverse histologic range, it often presents at an advanced stage in anatomically complex regions containing many vital structures. Morbidity is often high from both the disease and treatment, and long-term prognosis is often poor without close surveillance. Management may also differ dramatically depending on patient or tumor factors, complicating any systematic approach. Optimal care requires a dedicated multidisciplinary team of surgeons, radiation oncologists, medical oncologists, as well as specialists to facilitate posttreatment rehabilitation.

Numerous innovations in imaging, radiation therapy, and endoscopic skull base surgery have altered the approach taken when treating paranasal sinus cancer over the past decade. Higher-quality data and accumulated experience have led to greater insights into tumor biology, staging accuracy, and options for minimizing treatment morbidity and prolonging survival. Above all, practicing sound oncologic principles of complete resections with negative margins produce the best outcomes. We present the current consensus behind the etiology, diagnosis, and treatment of paranasal sinus malignancies.

Epidemiology

Paranasal sinus malignancies remain uncommon, and for classification purposes typically exclude nasopharyngeal cancers. They comprise less than 5% of all head and neck cancers, and the incidence varies somewhere between 0.5 and 1.0 per 100,000 people in Western countries and 3.6 per 100,000 people as reported in Japan. A significant majority of tumors occur at an older age (>50 to 60 years of age). While it appears that twice as many males are affected as women, this may be secondary to environmental or occupational hazards.

The maxillary sinus remains the most common site of paranasal sinus malignancies (50% to 70%), followed by the nasal cavity (15% to 30%) and ethmoid sinus (10% to 20%). Tumors arising from the frontal and sphenoid sinuses are rare, yet their involvement through tumor extension is highly suggestive of advanced disease and poor prognosis. Collectively, 5-year survival for all paranasal sinus malignancies is approximately 50%. Neck metastasis occurs in only 3% to 20% of patients, while distant metastasis occurs in 17% to 25% of patients. Caution must be exercised in extrapolating these numbers, as substantial differences arise depending on tumor histology. For instance, malignancies such as squamous cell carcinoma (SCC), sinonasal undifferentiated carcinoma (SNUC), and mucosal melanoma are known to be clinically more aggressive compared to esthesioneuroblastoma (also known as olfactory neuroblastoma [ONB]) and adenoid cystic carcinoma (ACC). SCC remains the most frequent histology in adults, while the most common pediatric sinonasal malignancy is rhabdomyosarcoma. Metastases from other primary cancers do present in the paranasal sinuses; the most commonly cited include those from breast, kidney, and prostate sites.

Pathology

Paranasal sinus malignancies can be classified into epithelial and nonepithelial categories ( Box 94.1 ). Unsurprisingly, a number of subtypes have been found to be caused by environmental or occupational toxic inhalants, with the highest risks found for workers in the wood, leather, textile, and aluminum industries. The most commonly encountered epithelial subtypes are SCC, ACC, and adenocarcinoma. Well-known nonepithelial subtypes include lymphoma (including natural killer/T-cell lymphoma, previously known as lethal midline granuloma) esthesioneuroblastoma, SNUCs, and mucosal melanoma. The World Health Organization comprehensively classifies the wide array of known sinonasal malignancies, with 44 distinct histologic entities. The most common subtypes will be discussed here.

Box 94.1
World Health Organization Histologic Classification of Paranasal Sinus Malignancies

Epithelial Malignancies

  • Squamous cell carcinoma

    • Verrucous carcinoma

    • Papillary squamous cell carcinoma

    • Basaloid squamous cell carcinoma

    • Spindle cell carcinoma

    • Adenosquamous carcinoma

    • Acantholytic squamous cell carcinoma

  • Lymphoepithelial carcinoma

  • Sinonasal undifferentiated carcinoma

  • Adenocarcinoma

    • Intestinal-type adenocarcinoma

    • Non-intestinal-type adenocarcinoma

  • Salivary gland-type carcinomas

    • Adenoid cystic carcinoma

    • Acinic cell carcinoma

    • Mucoepidermoid carcinoma

    • Epithelial-myoepithelial carcinoma

    • Clear cell carcinoma not otherwise specified

    • Myoepithelial carcinoma

    • Carcinoma ex pleomorphic adenoma

    • Polymorphous low-grade adenocarcinoma

  • Neuroendocrine tumors

    • Typical carcinoid

    • Atypical carcinoid

  • Small cell carcinoma, neuroendocrine type

Soft Tissue Malignancies

  • Fibrosarcoma

  • Malignant fibrous histiocytoma

  • Leiomyosarcoma

  • Rhabdomyosarcoma

  • Angiosarcoma

  • Malignant peripheral nerve sheath tumor

Bone and Cartilage Malignancies

  • Chondrosarcoma

  • Mesenchymal chondrosarcoma

  • Osteosarcoma

  • Chordoma

Hematolymphoid Malignancies

  • Extranodal natural killer/T-cell lymphoma

  • Diffuse large B-cell lymphoma

  • Extramedullary plasmacytoma

  • Extramedullary myeloid sarcoma

  • Histiocytic sarcoma

  • Langerhans cell histiocytosis

Neuroectodermal Malignancies

  • Ewing sarcoma

  • Primitive neuroectodermal tumor

  • Olfactory neuroblastoma

  • Melanotic neuroectodermal tumor of infancy

  • Mucosal malignant melanoma

Germ Cell Malignancies

  • Teratoma with malignant transformation

  • Sinonasal teratocarcinosarcoma

Squamous Cell Carcinoma

The most common of the sinonasal malignancies (40% to 50% incidence), SCC arises from the respiratory epithelium with varying squamous keratinization. Substantial evidence supports the hypothesis that smoking is a predominant risk factor, much as it is for other aerodigestive tract sites. Other risk factors linked to SCC include aflatoxin, chromium, nickel, and arsenic, among others. In terms of increased risk from exposure, a meta-analysis of 12 case-control studies identified an odds ratio of 13.9 for workers in the food preservation industry. A viral etiology is also associated with sinonasal SCC: HPV subtypes 6 and 11 are associated with inverted papilloma, of which approximately 10% degenerate into squamous cell malignancy.

SCCs tend to recur more quickly than other sinonasal subtypes, with mean recurrence reported to be 2 to 3 years. The incidence of regional neck metastasis may be relatively higher at 20% to 25%, which is suggestive of the possible need for elective neck dissection.

Adenocarcinoma

Adenocarcinomas make up between 13% and 19% of paranasal sinus malignancies, and their glandular architecture implies they arise from surface epithelium or seromucous glands. Besides those arising from minor salivary origin, adenocarcinomas are typically divided into non-intestinal and intestinal types. Non-intestinal adenocarcinomas convey a relatively good prognosis. Intestinal-type adenocarcinomas, which are histologically similar to colorectal adenocarcinomas, by contrast are locally aggressive with a high rate of spread to neck lymph nodes. The 5-year overall survival has been reported to be approximately 50%.

Among the known occupational hazards associated with paranasal sinus malignancies, the most indisputable causative connection has been with wood dusts, which have been described to convey up to a 900-fold increased risk in developing adenocarcinoma, specifically the intestinal type. Other pooled analyses have suggested an odds ratio for exposed males in wood-related occupations to be 13.5, increasing to 45.5 for longer duration of exposures. It appears that exposure for as little as 5 years can place workers at risk, whereby the latency before diagnosis is approximately 40 years. Leather-related dust exposure also appears associated with adenocarcinoma development, but to a lesser degree.

Adenoid Cystic Carcinoma

ACCs comprise 6% to 10% of paranasal sinus malignancies and are the most common sinonasal tumors of minor salivary gland origin. They are often classified by their tubular, cribriform, or solid growth pattern, with solid ACCs displaying the most aggressive biology. Of significant interest is ACC's high rate of perineural invasion and distant metastases over time, though its biologic behavior requires further investigation. While 5-year survival ranges from 73% to 90%, 15-year disease-specific survival falls to as low as 40%. Unlike SCC, the high recurrence rate takes many years to manifest.

Esthesioneuroblastoma

Esthesioneuroblastomas make up less than 5% of paranasal sinus malignancies and are of neuroectodermal origin derived from olfactory epithelium. They are characterized by a lobular appearance with neuroblasts and neurofibrils embedded among highly vascular fibrous stroma. The Kadish staging system has been the most widely accepted as an effective means to predict disease-free survival; group A tumors are limited to the nasal cavity, group B tumors extend only to the paranasal sinus, and group C tumors extend beyond the nasal cavity and sinuses. A modified Kadish system includes group D tumors, which have cervical lymphadenopathy or distant metastasis. Of note, esthesioneuroblastomas are typically radiosensitive but eventually develop cervical neck metastases in 20% to 25% of patients. This has prompted controversy about the utility of elective neck dissections or elective neck irradiation in patients with esthesioneuroblastoma. Approximately 50% of esthesioneuroblastomas are first discovered as Kadish group C, and these patients have reported 5-year survival rates of 50% to 70%.

Sinonasal Undifferentiated Neoplasm

SNUCs are aggressive, high-grade malignancies without clear squamous or glandular differentiation. The cells of origin remain unclear but potentially arise from Schneiderian epithelium or nasal ectoderm. Histologically solid sheets and nests of high-grade pleomorphic cells are identified with profuse mitotic figures and necrosis. Immunohistochemistry for SNUCs is nonspecific, lacking reactivity for neuroendocrine markers, but is useful to exclude similar entities such as esthesioneuroblastoma, with which it was originally classified. The clinical presentation of SNUCs is often rapid growth and extensive disease, with more than 80% of patients demonstrating T4 lesions at presentation. Trimodality treatment including surgery, radiation, and chemotherapy is typically recommended if able to be tolerated. Many patients have disease that is unresectable, and for those who are surgical candidates, the appropriate order of treatment (neoadjuvant versus postoperative chemoradiation) remains unclear. Nodal disease has been reported at 26% to 27%, meriting consideration of elective treatment of the bilateral necks. The 5-year overall survival is 22% to 43%, with as many as 65% of patients developing distant metastases.

Mucosal Melanoma

While it is comparatively less common in the paranasal sinuses than the other tumor types discussed here, the sinonasal cavities are the most frequent site for mucosal melanomas in the head and neck. Mucosal melanomas comprise less than 1% of all melanomas and are commonly less pigmented than cutaneous lesions, though they similarly stain positive for S-100, HMB-45, and melanin A. They also behave differently enough to merit their own staging system, as cutaneous predictors such as lactate dehydrogenase (LDH) or Breslow depth have not been historically shown to affect survival. Mucosal melanomas are extremely aggressive, with all lesions classified as T3 and Stage 3 at minimum. While surgical resection remains the standard of care, the majority of patients ultimately develop distant metastases, with the most common sites being lung, liver, and bone. The 5-year overall survival has been reported to be between 25% and 42%.

Rhabdomyosarcoma

Among pediatric patients, rhabdomyosarcomas are the most common paranasal sinus malignancy, with the orbit being the most common subsite overall. Rhabdomyosarcomas are derived from primitive mesenchymal tissue with myogenic differentiation and are among the tumors with small round blue cells found on histology. Current histologic classification subdivides rhabdomyosarcoma into four categories. The embryonal type is the most common variant (55% to 65% incidence) and typically affects infants and younger children. Within the embryonal classification are botryoid and spindle cell subtypes, generally considered to have the most favorable prognosis. The alveolar type (20% to 30% incidence) more often occurs in teens and has poorer prognostic potential, usually requiring more intensive multimodality treatment. The anaplastic type (previously termed pleomorphic type) largely affects adults, while the undifferentiated type is ill-defined with no obvious histologic myogenesis or differentiation. Both of these types harbor poor prognoses due to rapid growth and high rate of distant spread.

In the head and neck, biopsy only is typically performed given the presence of critical structures nearby, as recurrence can be high despite aggressive resection. Some protocols advocate neoadjuvant chemoradiation to make tumors more amenable to resection. Overall, 5-year overall survival is high, especially for orbital rhabdomyosarcoma at 95%, while for parameningeal sites it is 74%.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here